Click HERE to download the PDF version

Matthieu Giraud PhD
Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platforms
CordenPharma International

Advances in drug delivery, new technology, and a deeper understanding of oligonucleotides have led to escalating interest in developing these promising compounds. Research on these chemically synthesized compounds began about 50 years ago to address a wide range of conditions considered “undruggable” with small-molecule therapeutics. While development, delivery and regulatory challenges along with trial failures discouraged many developers, there has been a renewal of interest in oligonucleotides since early 2014, according to the numbers of NCEs entering clinical Phase I.

CLINICAL TRIALS: DELAYED PROGRESS

Today, about 170 ...